Shire sells off mRNA platform to RaNA
Shire has sold off its messenger RNA therapy platform MRT to Cambridge, Massachusetts-based RaNA Therapeutics.
Read More
Tag: urea cycle disorders
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
